晚期三阴性乳腺癌免疫治疗主旋律

Hope Rugo reports on key results from ESMO Congress 2021 on LBA16 - Final results of KEYNOTE-355: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer